Cargando…
Engineering anti-cancer nanovaccine based on antigen cross-presentation
Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules, thereby activating CD8(+) T cells, contributing to tumor elimination through a mechanism known as antigen cross-presentation. A variety of factors such as maturation state of DCs, co-stimula...
Autores principales: | Warrier, Vaishnavi U., Makandar, Amina I., Garg, Manoj, Sethi, Gautam, Kant, Ravi, Pal, Jayanta K., Yuba, Eiji, Gupta, Rajesh Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822533/ https://www.ncbi.nlm.nih.gov/pubmed/31652460 http://dx.doi.org/10.1042/BSR20193220 |
Ejemplares similares
-
Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy
por: Makandar, Amina I., et al.
Publicado: (2022) -
Ultradeformable Archaeosomes for Needle Free Nanovaccination with Leishmania braziliensis Antigens
por: Higa, Leticia H., et al.
Publicado: (2016) -
Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
por: Dong, Ying, et al.
Publicado: (2020) -
The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8(+) T Cell Responses
por: Kim, Cheol Gyun, et al.
Publicado: (2019) -
Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells
por: Liu, Wen-Long, et al.
Publicado: (2019)